Results from a recent population-based cohort study have indicated that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may increase the risk of developing neovascular age-related macular degeneration (nAMD) in patients with diabetes.1
GLP-1 RAs are one of the most beneficial treatments for type 2 diabetes; it increases glucose transporter expression in pancreatic cells, which facilitate glucose movement across the cell membrane. The medication also introduces pancreatic cells to secrete insulin in response to increased glucose content. GLP-1 RAs are one of the most widely used treatments in the world for diabetes and obesity.2
However, GLP-1 RAs have also exhibited adverse events. In two major phase 3a trials, GLP-1 RAs were associated with a higher risk of diabetic retinopathy (DR) and a .8% higher proportion of…